Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 18/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.64 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.61 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.59 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13079048 | 0.91 | PSMB5 (0.64) | PSMB5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13079069 | 0.91 | PSMB5 (0.65) | PSMB5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13079060 | 0.90 | PSMB5 (0.61) | PSMB5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13554123 | 0.90 | PSMB5 (0.66) | PSMB5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL554947 | 0.90 | PSMB5 (0.66) | PSMB5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13554073 | 0.90 | PSMB5 (0.66) | PSMB5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12518815 | 0.90 | PSMB5 (0.66) | PSMB5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12517364 | 0.90 | PSMB5 (0.66) | PSMB5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2927497 | 0.90 | PSMB5 (0.58) | PSMB5HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13079072 | 0.89 | PSMB5 (0.66) | PSMB5HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283367-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468383-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075936-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | PSMB5 2/4885HDAC3 809/4885HDAC4 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.